Market news

HCA's rising admissions and shorter hospital stays could help it meet growing patient demand while using existing capacity more efficiently.

HCA Healthcare's healthy volume growth faces payer-mix pressure, but cost controls, network expansion and Medicaid payments may support earnings growth.

Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495, $52, $120, $270 and $70.

HCA Healthcare, Inc. (NYSE:HCA) announced on September 15 that it had completed its acquisition of The College of Health Care Professions. The institution serves more than 8,000 students annually through 10 Texas campuses and online programs, offering more than 20 accredited healthcare programs. For HCA Healthcare, Inc. (NYSE:HCA), the opportunity is to connect education more […]

Frank Cappelleri of CappThesis breaks down the technicals on this name.

HCA Healthcare recently cut its full-year 2026 earnings guidance, citing a worsening payer mix after Affordable Care Act subsidy expirations, softer high-margin elective surgeries, and rising costs that also prompted targeted corporate and support-function layoffs and at least one hospital divestiture. These actions, alongside an estimated US$400 million quarterly revenue impact from payer shifts and an ongoing legal review of prior disclosures, highlight how policy-driven reimbursement...

Pomerantz Law Firm has launched an investigation into potential securities fraud and unlawful business practices at HCA Healthcare (NYSE:HCA). The probe focuses on whether HCA Healthcare and certain executives misled investors or breached fiduciary duties. The investigation could lead to future legal claims on behalf of shareholders depending on its findings. This kind of legal scrutiny highlights broader questions about risk, disclosure and income reliability across the healthcare sector...

HCA Healthcare (HCA) shares remain under pressure after the company cut its 2026 profit guidance, citing a weaker payer mix that reduced quarterly revenue by about $400 million and triggered fresh investor scrutiny. Against that backdrop, HCA Healthcare’s recent share price moves have been choppy, with a 1 day share price return of 1.78% after the guidance cut, a 90 day share price return of 9.96%, and a year to date share price decline of 13.01% at a last close of US$409.20. The 3 year total...

HCA Healthcare has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

First Eagle Investment Management, an investment management company, released its Q2 2026 investor update for “First Eagle Global Fund”. The letter can be downloaded here. Easing tensions in the Middle East led to a strong rally in risk markets in Q2. The S&P 500 Index rose 15.2%, while the MSCI EAFE Index gained 10.8%. Growth […]

HCA Healthcare's resiliency program is helping control costs amid payer pressures, potentially supporting long-term profitability and EBITDA growth.

Despite trailing the broader market over the past year, HCA Healthcare continues to command a moderately optimistic outlook from Wall Street analysts, who see room for further upside in the stock.

NASHVILLE, Tenn., August 20, 2026--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences:

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across Wall Street. In its Q2 results, HCA Healthcare, Inc. reported that […]

HCA Healthcare (NYSE:HCA) is facing nationwide union led protests as workers press for higher wages and improved staffing during ongoing contract negotiations. Union organizers say demonstrations span multiple HCA Healthcare facilities across the US and focus on pay, staffing ratios, and working conditions. The dispute centers on how HCA Healthcare allocates resources, including reported profits and share buybacks, relative to frontline labor costs and staffing levels. These protests...

HCA Healthcare has appointed Michael Schlosser, M.D., as executive vice president and chief clinical officer and created a new Ambulatory Operations Group led by Charles Gressle, consolidating oversight of clinical services, digital transformation, and more than 2,700 outpatient facilities as part of a broad leadership realignment that began taking effect in 2026. An interesting angle for investors is that Schlosser will simultaneously run HCA’s Clinical Services Group and its digital...

Detailed price information for Hca Holdings Inc (HCA-N) from The Globe and Mail including charting and trades.

Detailed price information for Hca Holdings Inc (HCA-N) from The Globe and Mail including charting and trades.

Bill Rutherford, who served on the finance team of the Tennessee-based healthcare giant for decades, reflects on his career in health as he switches to board service in retirement.

NASHVILLE, Tenn., August 06, 2026--HCA Healthcare, Inc. (NYSE:HCA) today announced that Michael Schlosser, M.D., MBA, senior vice president and chief transformation officer, has been appointed executive vice president and chief clinical officer, effective Sept. 1, 2026.

The hospital juggernaut is adding Texas MedClinic’s locations to its nationwide portfolio of urgent care clinics amid rising consumer demand for fast and convenient medical attention.

HCA Healthcare delivered solid results in the second quarter, with revenue and earnings per share both ahead of Wall Street expectations. The positive market reaction reflected management’s ability to navigate significant headwinds, particularly an unexpected increase in uninsured patient volumes following the expiration of enhanced premium tax credits. CEO Samuel N. Hazen highlighted that while overall patient demand remained robust—especially for emergency services—unfavorable payer mix shifts

HCA's Q2 results beat expectations. Company resets 2026 guidance on HIX headwinds and decline in surgeries.

HCA Healthcare's Q2 earnings beat expectations with $20.23B in revenue and adjusted earnings of $7.59 per share. Analysts lower price targets.

Independent monitors flagged recurring non-compliance issues tied to HCA Healthcare's acquisition of Mission Health for a third consecutive year. Concerns include discontinued industrial rehabilitation services, reduced access to services at Mission Hospital and affiliated facilities, and a Medicare termination notice. The findings focus attention on operational, regulatory, and reputational risks for NYSE:HCA as it manages this acquired network. HCA Healthcare, one of the largest for...

Moby summary of HCA Healthcare, Inc.'s Q2 2026 earnings call

HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.

While the top- and bottom-line numbers for HCA (HCA) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

HCA (HCA) delivered earnings and revenue surprises of +0.26% and 0.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Hospital operator HCA Healthcare (NYSE:HCA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 8.7% year on year to $20.23 billion. The company expects the full year’s revenue to be around $78.25 billion, close to analysts’ estimates. Its GAAP profit of $7.62 per share was 2.2% above analysts’ consensus estimates.